Burden and Treatment of Achondroplasia: A Systematic Literature Review
ConclusionsThis SLR provides a comprehensive overview of the current burden and treatment landscape for achondroplasia, along with areas where evidence is lacking. This review should be updated as new evidence becomes available on emerging therapies. (Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale
ConclusionIt is feasible to value different dimensions of cognition separately using a validated instrument for proxy assessment. The resulting utilities indicate loss of quality of life due to reduced cognitive functioning. (Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Characterizing Opioid Use Disorder Encounters in the Midwest Region, USA
ConclusionCompared to East North Central, patient encounters of OUD were more frequent and the average length of stay was longer than in West North Central. A significantly higher proportion of patient encounters in West North Central were associated with patients being male, African American, and single, and facilities being in rural areas. (Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies
ConclusionsThese results highlight the benefit of pirfenidone treatment in patients with advanced and non-advanced IPF. As such, the indication for pirfenidone in the EU has now been updated to include the treatment of adult patients with advanced IPF.Trial RegistrationsASCEND (NCT01366209), CAPACITY 004 (NCT00287716), CAPACITY 006 (NCT00287729), RECAP (NCT00662038), PASSPORT (NCT02699879), and SP-IPF (NCT02951429). (Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn ’s Disease
ConclusionsThis indirect comparison demonstrated higher rates of clinical and endoscopic outcomes during induction for RZB compared to UST; CDAI remission following maintenance was comparable. Direct comparisons of RZB and UST are warranted to validate these findings. (Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
(Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations
AbstractDue to the diverse mechanisms of action of antiseizure drugs, there has been a rise in prescriptions of these drugs for non-epileptic pathologies. One drug that is now being used for a variety of conditions is topiramate. This is a narrative review that used PubMed, Google Scholar, MEDLINE, and ScienceDirect to review literature on the clinical and pharmacologic properties of topiramate. Topiramate is a commonly prescribed second-generation antiseizure drug. The drug works through multiple pathways to prevent seizures. In this regard, topiramate blocks sodium and calcium voltage-gated channels, inhibits glutamate r...
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Application of Autologous Hair Transplantation Technique in Children with Cicatricial Alopecia
ConclusionAutologous hair transplantation technology is a safe and effective method for children with cicatricial alopecia. (Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective
ConclusionIn concert with early diagnosis and proactive management of CKD, the expansion of the gliflozin indications into the French CKD population presents the opportunity to reduce the substantial burden associated with cardio-renal complications which outweighs the additional cost of the new treatment.Infographic (Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely
AbstractDuring the last 15 years, tremendous efforts have been made toward medical treatment of metastatic renal cell carcinoma (mRCC). Checkpoint inhibitors (CPI) and tyrosine kinase inhibitors (TKI) dominate the therapeutic armamentarium, as a combination of either CPIs or CPI/TKI, while the value of TKI monotherapy is de creasing. With increasing efficiency, however, toxicity also increases. Appropriate management of adverse events is therefore pivotal. Recognizing adverse events, judging their etiology and appropriate management, and sometimes expanding the diagnostics of adverse events are mandatory and demand exp e...
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19
(Source: Advances in Therapy)
Source: Advances in Therapy - August 16, 2023 Category: Drugs & Pharmacology Source Type: research
Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis
AbstractBrain metastases are especially common in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), with a cumulative incidence of over 50% and associated with a poor prognosis, high symptom burden, and decreased quality of life. Lorlatinib is a brain-penetrant, third-generation ALK tyrosine kinase inhibitor (TKI), which has a high potency against resistance mutations seen with earlier generation ALK TKIs. In 2018, lorlatinib was granted accelerated approval in second- and third-line treatment for use in patients withALK-positive metastatic NSCLC on the basis of phase 1/2 study results. This i...
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research
Key Device Attributes for Injectable Somatostatin Receptor Ligand Therapy in Acromegaly and Neuroendocrine Tumours
ConclusionThe results identified key features of injection devices for SRL therapy which merit consideration for optimal management and underscore the importance of patient partnership in treatment decisions. (Source: Advances in Therapy)
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
ConclusionGiven the limited real-world efficacy onEGFR-mutant NSCLC resistant to osimertinib and platinum-based chemotherapy, the development of more highly potent post-treatment therapies is warranted. (Source: Advances in Therapy)
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research
Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy)
AbstractUterine fibroids (UF) are common benign tumors in women and are an important health concern in the US and globally. UF can severely compromise a woman's quality of life, thus making it an important health issue. In this podcast, a professor of Obstetrics and Gynecology, University of Chicago (Dr. Ayman Al-Hendy) and the CEO of the Fibroid Foundation (Sateria Venable) provide their perspectives on the diagnosis and management of UF, including common treatments (e.g., myomectomy or hysterectomy). They also discuss Relugolix combination therapy for UF, noting who could benefit from this treatment and how it works. Pod...
Source: Advances in Therapy - August 12, 2023 Category: Drugs & Pharmacology Source Type: research
